Therapeutic vaccines in solid tumours: Can they be harmful?
- 31 August 2009
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 45 (12), 2087-2090
- https://doi.org/10.1016/j.ejca.2009.05.004
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Melanoma and ImmunotherapyHematology/Oncology Clinics of North America, 2009
- Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with VaccinesClinical Cancer Research, 2008
- Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced MelanomaJournal of Clinical Oncology, 2008
- The role of vaccine therapy in the treatment of melanomaExpert Opinion on Biological Therapy, 2008
- Randomized Adjuvant Therapy Trials in Melanoma: Surgical and SystemicSeminars in Oncology, 2007
- Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOGAnnals of Oncology, 2006
- Cancer immunotherapy: moving beyond current vaccinesNature Medicine, 2004
- Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?European Journal Of Cancer, 2004
- Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanomaNature Medicine, 1998
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cellsNature Medicine, 1998